Peter Bains

Peter has more than three decades of leadership experience in the bio pharmaceutical industry including senior strategic and operational roles in a 20-year career with GSK. He more recently served as CEO of Syngene ,where he led a successful IPO and listing in India, and Sosei Heptares, a Japanese publicly listed company, where he led the acquisition of Heptares. Peter currently serves on the Boards of MiNA Therapeutics, a private UK biotech where he is also CBO, Indivior, a FTSE-listed public company, and he is a Managing Partner of Twiga Group LLC.